The goal of this website/working group is to present information in an understandable, readable fashion that targets key points pertinent to individuals offering first-line care for patients with ARS or CRS.

Rhinosinusitis is a frequently occurring disease, with significant impact on quality of life and health care spending, and economic impact in terms of absenteeism and productivity. It is estimated that approximately 6 billion dollars is spent in the United States annually on therapy for rhinosinusitis. A recent study in Canada described the impact of chronic rhinosinusitis (CRS) on patients and healthcare utilization. Patients with CRS had a health status similar to patients with arthritis, cancer, asthma, and inflammatory bowel disease. Compared with people without CRS, those with CRS reported more days spent bedridden and more visits to family physicians, alternative healthcare providers, and mental health experts. These findings underscore the significant impact of this disease on patient quality of life, as well as costs of care to patients and society.